• Active Biotech’s third-quarter 2026 net loss widened 38% year over year to SEK 8.3 million.
• Operating expenses rose 42% to SEK 8.5 million year over year, while no net sales were recorded.
• Cash and cash equivalents fell 44% from year-end 2025 to SEK 36.3 million at September 30, 2026.
• The first cohort under the amended HOVON 172 myelofibrosis protocol completed safety evaluation in October; enrollment continued.
• A new collaboration with MPN-RC expanded US development activities for tasquinimod in myelofibrosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Active Biotech AB published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.